Topiramate: An effective add-on treatment in obese, drug-naïve patients with type 2 diabetes

September 2007
Formulary;Sep2007, Vol. 42 Issue 9, p560
Academic Journal
The article reports on the result of a study which demonstrated topiramate as an effective add-on treatment to lifestyle changes in obese patients with type 2 diabetes in the U.S. The use of topiramate was also associated with significant reductions in weight, blood pressure and urinary albumin excretion. According to researchers, the risk of adverse events should be weighted against the benefits of treatment with topiramate.


Related Articles

  • THE NEW PRESCRIPTIONS.  // Marie Claire (US Edition);Oct2012, Vol. 19 Issue 10, p270 

    The article offers a preview on the two diet medications approved by the U.S. Food and Drug Administration (FDA), the Belviq and the combined phentermine and topiramate drug called Qsymia and another drug, the Contrave, which is to be reviewed by the agency after it was rejected in 2011.

  • Phentermine/Topiramate (Qsymia) for Chronic Weight Management. GAZEWOOD, JOHN D.; BARRY, KATHLEEN // American Family Physician;10/15/2014, Vol. 90 Issue 8, p576 

    The article presents a drug review on the mechanism of action and efficacy of phentermine/topiramate (Qsymia) for chronic weight management. Topics discussed include potential safety issues in using the drug such as nephrolithiasis, cardiac risk, and teratogenicity, common side effects of the...

  • The skinny on errors with obesity drug names.  // Pharmacy Today;May2015, Vol. 21 Issue 5, p88 

    The article offers information on medications related to or used in the treatment of obesity. Topics discussed include potential confusion between the trade names Xeloda, an anticancer medication, and Xenical, an antiobesity drug, rules created by a hospital unto its computer system to alert...

  • Cost-Effectiveness Analysis of Qsymia for Weight Loss. Finkelstein, Eric; Kruger, Eliza; Karnawat, Sunil // PharmacoEconomics;Jul2015, Vol. 33 Issue 7, p699 

    Background: Phase 3 clinical trial results reveal that Qsymia is a clinically effective long-term treatment for obesity, but whether this treatment is cost-effective compared to a diet and lifestyle intervention has yet to be explored. Objective: To quantify the incremental cost-effectiveness of...

  • Intragastric Balloon in Association with Lifestyle and/or Pharmacotherapy in the Long-Term Management of Obesity. Farina, Maria; Baratta, Roberto; Nigro, Angela; Vinciguerra, Federica; Puglisi, Concetta; Schembri, Roberto; Virgilio, Clara; Vigneri, Riccardo; Frittitta, Lucia // Obesity Surgery;Apr2012, Vol. 22 Issue 4, p565 

    Background: Intragastric balloon (BioEnterics Intragastric Balloon, BIB®) or pharmacotherapy are possible options for the treatment of obese patients when traditional approaches have failed. The aim of our study was to compare in obese patients the effect on weight loss and metabolic changes...

  • Recent Advances in Obesity Pharmacotherapy. Mayer, Marcos A.; Höcht, Christian; Puyó, Ana; Taira, Carlos A. // Current Clinical Pharmacology;Jan2009, Vol. 4 Issue 1, p53 

    Obesity is considered a worldwide epidemic. Weight reduction by means of lifestyle changes is difficult to achieve, and pharmacotherapy is frequently needed. Although all currently approved anti-obesity agents have proven to be effective to achieve some degree of weight reduction and improve...

  • Choosing the Right Weight Loss Medication for Your Patient Requires Careful Consideration. Still, Christopher // Bariatric Times;Dec2015, Vol. 12 Issue 12, p3 

    The author discusses how to match a patient with the right weight loss medication given his risk, medical history and preferences. He cites the 5 Food and Drug Administration (FDA) approved pharmacotherapy options for treating obesity including phentermine, orlistat and phentermine/topiramate...

  • Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Garvey, W. Timothy; Ryan, Donna H.; Look, Michelle; Gadde, Kishore M.; Allison, David B.; Peterson, Craig A.; Schwiers, Michael; Day, Wesley W.; Bowden, Charles H. // American Journal of Clinical Nutrition;Feb2012, Vol. 95 Issue 2, p297 

    Background: Obesity is a serious chronic disease. Controlled-release phentermine/topiramate (PHEN/TPM CR), as an adjunct to lifestyle modification, has previously shown significant weight loss compared with placebo in a 56-wk study in overweight and obese subjects with ≥2 weight-related...

  • A near-empty diet market welcomes new antiobesity drug. Portyansky, Elena // Drug Topics;1/5/98, Vol. 142 Issue 1, p23 

    Focuses on the introduction of Meridia to the antiobesity market. Information on the drug's labeling warning; Details on clinical trials conducted on the drug; Side effects of the drug.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics